BenzingaAugust 14, 2026 at 8:16 AM NY21 days ago

JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25

JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story